Leukemia, B-Cell clinical trials
The registry lists 125 studies for Leukemia, B-Cell across more than 10 countries. 46 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Recruiting
- 32
- Status unknown
- 31
- Completed
- 19
- Active, not recruiting
- 18
- Not yet recruiting
- 13
- Terminated
- 5
Phase
- Phase 1
- 68
- Phase 2
- 56
- Early Phase 1
- 7
- Phase 3
- 5
- Phase 4
- 2
Where
- China
- 49
- United States
- 47
- Spain
- 10
- Italy
- 10
- Germany
- 10
- United Kingdom
- 9
Who runs them
AstraZeneca (6) · Baylor College of Medicine (5) · National Cancer Institute (NCI) (4) · Chongqing Precision Biotech Co., Ltd (4) · Center for International Blood and Marrow Transplant Research (3) · Shenzhen Geno-Immune Medical Institute (3) · Chinese PLA General Hospital (3) · Nanfang Hospital, Southern Medical University (3)
Studies
Recruiting first, then most recently updated. Showing 50 of 125 — search for more.
- A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)Not yet recruitingNCT07709000Phase 21 country
- Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureRecruitingNCT06651970Phase 46 countries
- Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)RecruitingNCT04728893Phase 222 countries
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)RecruitingNCT009235071 country
- Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)RecruitingNCT06345027Phase 11 country
- Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKINot yet recruitingNCT07819214Phase 21 country
- Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic MalignanciesNot yet recruitingNCT07710781Not applicable
- Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United KingdomRecruitingNCT055576951 country
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingNCT06564038Phase 1/213 countries
- Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)RecruitingNCT07509151Phase 35 countries
- Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)RecruitingNCT05010564Phase 11 country
- Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With ZanubrutinibRecruitingNCT06812715Phase 21 country
- Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell StudiesEnrolling by invitationNCT024737571 country
- CAR-T Immunotherapy Targeting CD19- ALLNot yet recruitingNCT04016129Phase 1/21 country
- Caloric Restriction and Activity to Reduce Chemoresistance in B-ALLRecruitingNCT05082519Phase 21 country
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT05254743Phase 323 countries
- Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.RecruitingNCT06762431Phase 1/21 country
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruitingNCT07342478Phase 31 country
- A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.RecruitingNCT06542250Phase 1/210 countries
- A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell MalignanciesRecruitingNCT06708897Phase 11 country
- CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesRecruitingNCT05442515Phase 1/21 country
- Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing VenetoclaxNot yet recruitingNCT07691047Not applicable1 country
- A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL PatientsRecruitingNCT07671378Phase 21 country
- Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).Not yet recruitingNCT07624799Phase 2
- U96-CAR-T-Cells For R/R B-ALLNot yet recruitingNCT07511426Phase 11 country
- The OPAL Study: AVM0703 for Treatment of Lymphoid MalignanciesRecruitingNCT04329728Phase 1/21 country
- CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT06208735Phase 11 country
- CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLLRecruitingNCT07487428Not applicable1 country
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationRecruitingNCT06859424Phase 21 country
- A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received BlinatumomabRecruitingNCT074223371 country
- Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyRecruitingNCT063577544 countries
- Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative NeoplasmsNot yet recruitingNCT07337967
- Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)Not yet recruitingNCT07166549Phase 11 country
- A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLLNot yet recruitingNCT06979076Phase 1/2
- Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHLNot yet recruitingNCT05779930Early Phase 11 country
- Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic LeukemiaNot yet recruitingNCT07113132
- CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and LymphomaRecruitingNCT06834529Phase 1/21 country
- CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHLRecruitingNCT06346912Early Phase 11 country
- CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+RecruitingNCT06355739Not applicable1 country
- INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic LeukemiaNot yet recruitingNCT06209671Phase 1
- Precision Exercise in Children With Malignant HemopathiesRecruitingNCT04090268Not applicable1 country
- CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.RecruitingNCT03614858Phase 1/21 country
- A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell MalignanciesRecruitingNCT05932173Phase 1/21 country
- Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell MalignanciesRecruitingNCT05487651Phase 11 country
- CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaRecruitingNCT04271410Phase 1/21 country
- A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and LeukemiaRecruitingNCT03383952Phase 11 country
- Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell TransplantationCompletedNCT01087294Phase 11 country
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesActive, not recruitingNCT05589896Phase 1/21 country
- Combination CAR-T Cell Therapy Targeting Hematological MalignanciesTerminatedNCT03125577Phase 1/21 country
- A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell MalignanciesTerminatedNCT03050190Not applicable1 country